NEW YORK (GenomeWeb) – Biocept said today that Columbia University Medical Center is planning a study that will evaluate its Target Selector liquid biopsy platform for detecting leptomeningeal metastases in patients with breast cancer.
LM is a condition in which cancer cells gain access to the cerebral spinal fluid, allowing them to seed metastases in the nerve tissue of the spine and brain.